Watch CTNM. Know when insiders buy.
One email the day a filing lands. Free.
CTNM
Contineum Therapeutics, Inc.
15.94
−0.76 −4.55%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
74
PASS · insiders 48, shorts 100
Insiders, 90 days
−$41K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $368.2MP/E —DIV YIELD —FCF YIELD -14.52%REV TTM —NET INCOME −$57.6MNET CASH —52W 9.17 – 17.57SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$17.4M | −$15.2M | — | -0.40 | −$11.5M | $6K | −$11.5M | Jul 30 |
| Q1 2026 · Mar 31 | — | — | — | −$16.9M | −$14.5M | — | -0.39 | −$16.3M | $312K | −$16.6M | Jul 30 |
| Q4 2025 · Dec 31derived | — | — | — | −$17.1M | −$15.2M | — | -0.49 | −$13M | $42K | −$13.1M | Mar 5 |
| Q3 2025 · Sep 30 | — | — | — | −$14.9M | −$12.8M | — | -0.45 | −$12.2M | $98K | −$12.3M | Oct 30 |
| Q2 2025 · Jun 30 | — | — | — | −$17.9M | −$16M | — | -0.62 | −$15.7M | $44K | −$15.7M | Jul 30 |
| Q1 2025 · Mar 31 | — | — | — | −$18.1M | −$16M | — | -0.62 | −$14.4M | $47K | −$14.5M | Jul 30 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$17M | −$14.6M | — | -0.57 | −$10.2M | $166K | −$10.4M | Mar 5 |
| Q3 2024 · Sep 30 | $0 | — | — | −$13M | −$10.3M | — | -0.40 | −$6.2M | $82K | −$6.3M | Oct 30 |
| Q2 2024 · Jun 30 | $0 | — | — | −$10.9M | −$9M | — | -0.39 | −$8.5M | $119K | −$8.6M | Oct 30 |
| Q1 2024 · Mar 31 | — | — | — | −$9.9M | −$8.4M | — | -3.55 | −$8M | $147K | −$8.1M | Oct 30 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$9.7M | −$7.8M | — | -0.35 | −$10.7M | $309K | −$11M | Mar 6 |
| Q3 2023 · Sep 30 | $0 | — | — | −$8.1M | −$6.3M | — | -2.69 | −$5.4M | $22K | −$5.4M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$68.1M | −$60M | — | -2.17 | −$55.3M | $231K | −$55.5M | — | — |
| FY2024 · to Dec 31 | $0 | — | −$50.9M | −$42.3M | — | -2.18 | −$32.8M | $514K | −$33.4M | — | — |
| FY2023 · to Dec 31 | $50M | — | $16.1M | $22.7M | 45.4% | 0.08 | $19.3M | $414K | $18.9M | — | — |
Every number comes from Contineum Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.